Landewé RBM, van der Heijde D, Dougados M, et al. - This study was attempted to compare dose continuation, reduction and withdrawal of the tumour necrosis factor inhibitor certolizumab pegol (CZP) following achievement of sustained remission in patients with early axial spondyloarthritis (axSpA). Individuals received CZP 200 mg every 2 weeks (Q2W) during the 48-week open-label induction period. At Week 48, Individuals in sustained remission (Ankylosing Spondylitis Disease Activity Score < 1.3 at Weeks 32/36 and 48) were assigned randomly to double-blind CZP 200 mg Q2W (full maintenance dose), CZP 200 mg every 4 weeks (Q4W; reduced maintenance dose) or placebo (withdrawal) for a further 48 weeks. This study's findings show that at 48 weeks, individuals with early axSpA who achieve sustained remission can reduce their CZP maintenance dose; nevertheless, it was noted that treatment should not be completely discontinued due to the high risk of flare following CZP withdrawal.